These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Narrow interval dual phase 18F-FDG PET/CT: A practical approach for distinguishing tumor recurrence from radiation necrosis in brain metastasis. Aggarwal A; Aggarwal AK; Prakash S; Vile DJ; Aggarwal A Medicine (Baltimore); 2024 May; 103(18):e37789. PubMed ID: 38701250 [TBL] [Abstract][Full Text] [Related]
4. Distinguishing Tumor Recurrence From Radiation Necrosis in Treated Glioblastoma Using Multiparametric MRI. Feng A; Yuan P; Huang T; Li L; Lyu J Acad Radiol; 2022 Sep; 29(9):1320-1331. PubMed ID: 34896001 [TBL] [Abstract][Full Text] [Related]
5. Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI. Kim YH; Oh SW; Lim YJ; Park CK; Lee SH; Kang KW; Jung HW; Chang KH Clin Neurol Neurosurg; 2010 Nov; 112(9):758-65. PubMed ID: 20619531 [TBL] [Abstract][Full Text] [Related]
6. Multiparametric Analysis Combining DSC-MR Perfusion and [18F]FET-PET is Superior to a Single Parameter Approach for Differentiation of Progressive Glioma from Radiation Necrosis. Panholzer J; Malsiner-Walli G; Grün B; Kalev O; Sonnberger M; Pichler R Clin Neuroradiol; 2024 Jun; 34(2):351-360. PubMed ID: 38157019 [TBL] [Abstract][Full Text] [Related]
8. A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation. Hatzoglou V; Yang TJ; Omuro A; Gavrilovic I; Ulaner G; Rubel J; Schneider T; Woo KM; Zhang Z; Peck KK; Beal K; Young RJ Neuro Oncol; 2016 Jun; 18(6):873-80. PubMed ID: 26688076 [TBL] [Abstract][Full Text] [Related]
9. (18)F-fluoromethylcholine (FCho), (18)F-fluoroethyltyrosine (FET), and (18)F-fluorodeoxyglucose (FDG) for the discrimination between high-grade glioma and radiation necrosis in rats: a PET study. Bolcaen J; Descamps B; Deblaere K; Boterberg T; De Vos Pharm F; Kalala JP; Van den Broecke C; Decrock E; Leybaert L; Vanhove C; Goethals I Nucl Med Biol; 2015 Jan; 42(1):38-45. PubMed ID: 25218024 [TBL] [Abstract][Full Text] [Related]
10. Comparison of (11)C-methionine, (11)C-choline, and (18)F-fluorodeoxyglucose-PET for distinguishing glioma recurrence from radiation necrosis. Takenaka S; Asano Y; Shinoda J; Nomura Y; Yonezawa S; Miwa K; Yano H; Iwama T Neurol Med Chir (Tokyo); 2014; 54(4):280-9. PubMed ID: 24305028 [TBL] [Abstract][Full Text] [Related]
11. Comparison of MRI, F-18 FDG, and 11C-choline PET/CT for their potentials in differentiating brain tumor recurrence from brain tumor necrosis following radiotherapy. Tan H; Chen L; Guan Y; Lin X Clin Nucl Med; 2011 Nov; 36(11):978-81. PubMed ID: 21975383 [TBL] [Abstract][Full Text] [Related]
12. Multiparametric Evaluation in Differentiating Glioma Recurrence from Treatment-Induced Necrosis Using Simultaneous Jena A; Taneja S; Jha A; Damesha NK; Negi P; Jadhav GK; Verma SM; Sogani SK AJNR Am J Neuroradiol; 2017 May; 38(5):899-907. PubMed ID: 28341716 [TBL] [Abstract][Full Text] [Related]
13. Differentiation of Recurrent Glioblastoma from Delayed Radiation Necrosis by Using Voxel-based Multiparametric Analysis of MR Imaging Data. Yoon RG; Kim HS; Koh MJ; Shim WH; Jung SC; Kim SJ; Kim JH Radiology; 2017 Oct; 285(1):206-213. PubMed ID: 28535120 [TBL] [Abstract][Full Text] [Related]
14. Comparison of the effectiveness of MRI perfusion and fluorine-18 FDG PET-CT for differentiating radiation injury from viable brain tumor: a preliminary retrospective analysis with pathologic correlation in all patients. Hatzoglou V; Ulaner GA; Zhang Z; Beal K; Holodny AI; Young RJ Clin Imaging; 2013; 37(3):451-7. PubMed ID: 23068052 [TBL] [Abstract][Full Text] [Related]
15. Comparison of Diffusion Tensor Imaging and Magnetic Resonance Perfusion Imaging in Differentiating Recurrent Brain Neoplasm From Radiation Necrosis. Masch WR; Wang PI; Chenevert TL; Junck L; Tsien C; Heth JA; Sundgren PC Acad Radiol; 2016 May; 23(5):569-76. PubMed ID: 26916251 [TBL] [Abstract][Full Text] [Related]
16. Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival. Hu LS; Eschbacher JM; Heiserman JE; Dueck AC; Shapiro WR; Liu S; Karis JP; Smith KA; Coons SW; Nakaji P; Spetzler RF; Feuerstein BG; Debbins J; Baxter LC Neuro Oncol; 2012 Jul; 14(7):919-30. PubMed ID: 22561797 [TBL] [Abstract][Full Text] [Related]
18. Differentiation between Treatment-Induced Necrosis and Recurrent Tumors in Patients with Metastatic Brain Tumors: Comparison among Tomura N; Kokubun M; Saginoya T; Mizuno Y; Kikuchi Y AJNR Am J Neuroradiol; 2017 Aug; 38(8):1520-1527. PubMed ID: 28619837 [TBL] [Abstract][Full Text] [Related]
19. Vascular architecture mapping for early detection of glioblastoma recurrence. Stadlbauer A; Eyüpoglu I; Buchfelder M; Dörfler A; Zimmermann M; Heinz G; Oberndorfer S Neurosurg Focus; 2019 Dec; 47(6):E14. PubMed ID: 31786560 [TBL] [Abstract][Full Text] [Related]
20. Utility of Dynamic Susceptibility Contrast Perfusion-Weighted MR Imaging and Qiao Z; Zhao X; Wang K; Zhang Y; Fan D; Yu T; Shen H; Chen Q; Ai L AJNR Am J Neuroradiol; 2019 Feb; 40(2):253-259. PubMed ID: 30655259 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]